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Background & aims: Impaired attention and response inhibition have been reported in patients with Crohn’s
disease (CD) in clinical remission. Prospective studies are needed to determine whether this is a stable feature of
CD and whether a similar impairment is evident in ulcerative colitis (UC). Thus, our aims were to examine
whether patients with CD and UC exhibited a persistent impairment in attentional performance, and if this
impairment was related to key biological indices of relevance to cognition.
Methods: A prospective observational study was conducted on fifteen patients with CD and 7 with UC in clinical
remission recruited from a specialty clinic and 30 healthy matched control participants. A neuropsychological
assessment was carried out at baseline (visit 1) and at a 6 month follow-up (visit 2). Plasma proinflammatory
cytokines, the plasma kynurenine:tryptophan (Kyn:Trp) ratio and the salivary cortisol awakening response (CAR)
were also determined at each visit.
Results: Across visits, patients with CD exhibited impaired attentional performance (p ¼ 0.023). Plasma IL-6 (P ¼
0.001) and the Kyn:Trp ratio (P ¼ 0.03) were consistently elevated and the CAR significantly blunted (P < 0.05)
in patients with CD. No significant relationships were identified between any biochemical parameter and altered
cognitive performance.
Conclusions: Impaired cognitive function is a stable feature of patients with CD. These data suggest that even
where remission has been achieved, the functional impact of an organic gastrointestinal disorder on cognition is
still evident. However, it is unclear at present if physiological changes due to disease activity play a role in
cognitive impairment in CD.1. Introduction
Over recent years the impact of psychosocial and psychological fac-
tors, via pathways along the brain-gut axis in inflammatory bowel disease
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symptoms in IBD (Qiu et al., 1999). Pathogenic processes such as chronic
inflammation may exert a significant influence on normal brain-gut
communications in IBD (Cryan et al., 2019; Dantzer, 2004) and it is
clear that a pro-inflammatory phenotype significantly increases the risk
of depression and anxiety related symptoms, both of which are
commonly found in patients with IBD (Goodhand et al., 2012). The
relationship between IBD disease activity and psychological disorders is
likely bidirectional (Gracie et al., 2018).
In a recent cross-sectional study, patients with Crohn’s disease (CD),
who were in remission at the time of testing, were found to exhibit
impaired attentional performance on a battery of neuropsychological
tests (Kennedy et al., 2014). Prior to this investigation a limited number
of cognitive assessments had been reported in IBD, with the most
consistent finding being reduced verbal IQ performance (Berrill et al.,
2013; Dancey et al., 2009). More recently, impaired neurocognitive and
psychomotor function across areas of convergent thinking, perceptive
abilities, sophisticated operative thinking, processing speed, verbal
learning, and delayed recall memory (Tadin Hadjina et al., 2019;
Whitehouse et al., 2019) as well as cognitive inflexibility have been re-
ported (Petruo et al., 2017). Attention and memory impairments have
also been reported in pediatric patients with IBD (Piasecki et al., 2017).
Nevertheless, and the despite the important association between
illness cognitions and quality of life (Gurkova and Soosova, 2018), there
are a paucity of investigations into cognitive performance in IBD and it
remains a largely overlooked aspect of the disease. Furthermore, the
nature of the biological processes mediating altered cognitive function in
patients in apparent remission are currently unknown although alter-
ations in brain white matter microstructural properties (Hou et al., 2020)
and functional disruption in the anterior cingulate cortex (ACC) and the
right inferior frontal gyrus have been noted (Petruo et al., 2017).
Inflammation, stress and the stress- and immune-mediated changes in the
metabolism of tryptophan along the kynurenine pathway are potential
mechanisms through which CNS function could be modulated (Kennedy
et al., 2012).
In this study, we carried out a prospective assessment of cognitive
performance in patients with both CD and UC in clinical remission at
each study visit in comparison to matched healthy control participants
(Kennedy et al., 2014). Based on our prior findings, our a priori hy-
pothesis was that these patients would display a consistent impairment
on a test of attentional performance. This was our primary outcome
measure, with visuospatial episodic memory as the main secondary
endpoint. We also tested the hypothesis that any impairments observed
were related to altered brain-gut axis signaling, due to the influence of
systemic inflammation, hypothalamic-pituitary-adrenal (HPA)-axis
dysfunction and related changes in metabolism of tryptophan along the
kynurenine pathway.
2. Methods
2.1. Study population
Participants from our preliminary investigation (Kennedy et al.,
2014) were re-enrolled for two follow-up assessments which were
designated as visit 1 and visit 2. Only IBD patients who were in remission
and remained in remission throughout the study were included. Remis-
sion was defined as a Harvey Bradshaw Index (HBI) score <5 for CD
(Cuffari et al., 2001) and a Short Clinical Colitis Activity Index (SCCAI)
score  3 for UC (Walmsley et al., 1998). Patients were recruited from a
specialty clinic at Cork University Hospital. Healthy control participants
were recruited via advertisement from the staff and student population of
University College Cork. Study participants were males and femails be-
tween 18 and 50 years of age. Exclusion criteria included use of psy-
choactive medications (including anxiolytics, antipsychotics,
antidepressants, and opioid based pain relievers), corticosteroid use in
the prior 4 weeks (budesonide, which has lower systemic bioavailability,2was allowed at time of testing), antibiotic use within the prior four
weeks, history of alcohol abuse and recent (within 6 months) abdominal
surgery.
2.2. Study procedures: Visit 1 and visit 2
The study protocol (APC024 2010) and all procedures were approved
by the University College Cork Clinical Research Ethics Committee of The
Cork Teaching Hospitals and conducted in accordance with the ICH
Guidelines on Good Clinical Practice, and the Declaration of Helsinki.
Study participants meeting inclusion criteria provided written informed
consent prior to any study procedures. A total of 52 participants were
assessed at visit 1 and 47 returned for 6 month follow-up at visit 2. A
maximum time window of plus or minus 4 weeks of a scheduled follow-
up visit date was permitted. At baseline, groups were matched on the
basis of age, verbal IQ and body mass index (BMI). At each visit, medical
history and a brief medical examination were carried out by an experi-
enced clinical research nurse who recorded participants’ vital signs, BMI,
noted all medications used by patients, and collected a venous blood
sample for research purposes (see below) and for assessment of full blood
count, renal function, serum electrolytes and liver enzymes. Clinically
significant abnormalities in these latter blood tests at visit 1 or 2 led to
exclusion from the study.
2.3. Measures
2.3.1. Anxiety & depression
Symptoms of anxiety and depression were assessed at visit 1 and 2
using the self-reported Hospital Anxiety and Depression Scale (HADS;
(Zigmond and Snaith, 1983)) and the Patient Health Questionnaire
(PHQ-9; (Kroenke et al., 2001)).
2.3.2. Proinflammatory cytokine sampling & analysis
At each visit, 10 ml of whole blood was collected in EDTA tubes.
Samples were centrifuged immediately at 1000g for 15 min and ali-
quoted plasma samples were frozen at 80 C until analysis. Plasma
levels of IL-6, IL-8, and TNF-α were assayed in duplicate using a high
sensitivity commercially available electrochemiluminescence MULTI-
SPOT® Meso Scale Discovery kit (MSD, Rockville, MD, USA) as per the
manufacturer’s instructions. The median lower limits of detection for
each cytokine are; IL-6- 0.06 pg/ml, IL-8- 0.04 pg/ml, TNF-α- 0.04 pg/
ml.
2.3.3. Kynurenine and tryptophan analysis
Tryptophan and kynurenine pathwaymetabolites were determined as
previously described (Clarke et al., 2009). Plasma samples were spiked
with internal standard (3-Nitro l-tyrosine) prior to being deproteinised by
the addition of 20 μl of 4M perchloric acid to 200 μl of sample. Samples
were centrifuged at 21000 g on a Hettich Mikro 22R centrifuge (AGB,
Dublin, Ireland) for 20 min at 4 C and 100 μl of supernatant transferred
to a HPLC vial for analysis on the HPLC system (UV and FLD detection).
All samples were injected onto a reversed phase Luna 3 μm C18 (2) 150
 2 mm column (Phenomenex), which was protected by Krudkatcher
disposable pre-column filters (Phenomenex) and SecurityGuard car-
tridges (Phenomenex). The mobile phase consisted of 50 mM acetic acid,
100 mM zinc acetate with 3% (v/v) acetonitrile and was filtered through
Millipore 0.45 μm HV Durapore membrane filters (AGB) and vacuum
degassed prior to use. Compounds were eluted isocratically over a
30-min runtime at a flow rate of 0.3 mls/min after a 20 μl injection. The
column was maintained at a temperature of 30 C and samples/standards
were kept at 8 C in the cooled autoinjector prior to injection. The
fluorescent detector was set at an excitation wavelength of 254 nm and
an emission wavelength of 404 nm. The UV detector was set to 330 nm.
L-tryptophan and kynurenine were identified by their characteristic
retention times as determined by standard injections which were run at
regular intervals during the sample analysis. Analyte: Internal standard
G. Clarke et al. Brain, Behavior, & Immunity - Health 5 (2020) 100093peak height rations were measured and compared with standard in-
jections and results were expressed as ng/ml of plasma.
2.3.4. Salivary cortisol analysis
HPA axis function was determined by measuring the salivary cortisol
awakening response (CAR) as previously described (Kennedy et al.,
2014). Saliva samples were stored at 80 C until analysis. Cortisol
concentrations were determined using the Cortisol Enzyme Immuno-
assay Kit as per manufacturers’ instruction (Enzo®, Life Sciences). Assay
detection limit was 0.16 nmol/L. Inter and intra assay % C.Vs were 8.7%
and 7.3% respectively.
2.3.5. Cognitive assessments
At visit 1 and 2, participants completed a computerized Stroop test
(Xavier Educational Software Ltd, Bangor, Wales), and the Paired Asso-
ciates Learning (PAL) test from the Cambridge Neuropsychological Test
Automated Battery (CANTAB®; Cambridge Cognition, LTD (Robbins and
Sahakian, 1994)). To confirm our preliminary finding that other cogni-
tive domains were not affected, participants were also assessed using the
Intra-Extradimensional Set Shift (IED) and Spatial Working Memory
(SWM) tests from the CANTAB®. Parallel versions of the PAL and IED test
were used at visit 1 and 2 to reduce practice effects. Parallel versions of
the SWM or Stroop tests are not available and the same versions were
used at each visit. The cognitive assessment lasted approximately 45 min
with each participant first completing the Big/Little Circle as a short
familiarization task, followed by the IED, PAL and SWM tests from the
CANTAB®, and finally the Stroop test. All assessments at visit 1 and 2
were conducted by a trained administrator who issued standardized
verbal instructions to participants on the use of a portable touch screen
Sahara i440D Slate Tablet PC (Sand Dune Ventures, Tablet Kiosk). A
measure of pre-morbid IQ was obtained using the National Adult Reading
Test-2 (NART-2, (Nelson and Willison, 1991) and converted to Wechsler
Adult Intelligence Scale-Revised (WAIS-R) full scale IQ scores. Detailed
information on CANTAB® tests are available elsewhere (Fray and Rob-
bins, 1996; Sahakian and Owen, 1992) and summarised below..
2.3.5.1. Stroop word color interference test (Stroop test). The Stroop is an
executive function test and specifically measures selective attention and
response inhibition. During the interference stage of the Stroop, inhibi-
tion of the prepotent response primarily engages the ACC, with general
Stroop performance also requiring input from a number of regions of the
temporal and parietal lobes (Alvarez and Emory, 2006; Botvinick et al.,
2004; Strauss et al., 2006). The computerized Stroop test used in the
current study is based on the Victoria Stroop Test as previously described
(Assef et al., 2007). Response speed in milliseconds (ms) is recorded on
each trial with an overall mean response time (MRT) for each of 3 stages
consisting of 24 trials. In stage 1, on each trial participants are required to
name a color word printed in the white [word naming]; Stage 2, on each
trial participants name the color of a line of stars which appear on screen
[color naming]; Stage 3, on each trial participants must name the color a
word is printed in, which is incongruent to the word it spells e.g. the word
‘blue’ printed in the color red, [interference stage]). The main outcome
measure is the Stroop effect, which is calculated by subtracting the MRT of
stage 3 [Interference Stage], from the MRT on stage 1 [word naming].
The Stroop effect was measured at visits 1 and 2.
2.3.5.2. Paired Associates Learning (PAL, Parallel mode). PAL is a visuo-
spatial episodic memory test which assesses new learning, list memory
and list learning, and has demonstrated sensitivity to changes in the
function of hippocampal brain regions (Blackwell et al., 2004; Owen
et al., 1995; Swainson et al., 2001; Sweeney et al., 2000). PAL also en-
gages a number of additional brain regions comprising a fronto-parietal
network during encoding phases, and posterior cingulate and left
cuneus regions during retrieval stages (de Rover et al., 2011). The main
outcome measure was Total errors (adjusted) assessed at visit 1 and 2.32.3.5.3. Intra-Extradimensional Set Shift (IED). The IED is an executive
function test and measures rule acquisition and reversal, attentional set
formation, maintenance and shifting (Downes et al., 1989; Sahakian and
Owen, 1992). Reversal learning involves ventral prefrontal cortex (PFC)
brain regions, while attentional set-shifting engages the dorsolateral PFC
(Nagahama et al., 2001). The main outcome measure was Total errors
(adjusted), assessed at visit 1 and 2.
2.3.5.4. Spatial Working Memory (SWM). The SWM is a working mem-
ory test which involves on-line monitoring and updating of information
and self-ordered searching. The SWM has shown sensitivity to frontal
lobe dysfunction (Owen et al., 1996; Robbins et al., 1998). The main
outcome measure was Total errors assessed at visit 1 and 2.2.6. Statistical analysis
Group characteristics (age, IQ and BMI) at visit 1 were analyzed by
one-way analysis of variance (ANOVA). Chi-square (χ2) was used to
examine gender distribution across groups. Changes in patient disease
activity measured using the HBI and SCCAI were assessed using paired
samples t-tests between visit 1 and 2. To allow for repeated measures
analysis and to avoid bias that may be introduced by using list-wise
deletion of incomplete cases (Graham, 2009; Rubin et al., 2007; Twisk
and de Vente, 2002), missing data analysis was performed on variables
subject to prospective analysis. In total, 5.5% of cognitive performance
data and 6.2% of biochemical measure data were missing at visit 2. We
first determined that data were missing completely at random (MCAR)
using Littles MCAR test ((Little, 1988); χ2 (150) ¼ 170.512, p ¼ 0.121)).
Single imputation was then performed using the
Expectation-maximization (EM) algorithm (Dempster et al., 1977) with
complete values at visit 1 as predictor variables to impute missing visit 2
values, as previously described (Guloksuz et al., 2013; Laaksonen et al.,
2011; Lintvedt et al., 2013). Following data imputation, normality checks
were performed. CANTAB ® variables were not normally distributed and
were transformed as follows: IED and PAL outcome variables were
normalized using logarithmic base 10 (log10) transformations and SWM
outcome variables normalized using square-root transformations. Plasma
cytokine & salivary cortisol data were not normally distributed and were
normalized using a natural logarithmic transformation (ln). Total cortisol
levels across the three collection time points at visit 1 and 2 were
determined using an area under the curve with respect to ground (AUCg)
analysis (Pruessner et al., 2003). Twenty-eight healthy control partici-
pants, 14 patients with CD and 6 patients with UC provided saliva sam-
ples as instructed and useable for analysis at Visit 1. One IL-6 sample and
one IL-8 sample from two separate patients with UC were out of the
detection range and cytokine imputation and repeated measures analysis
was conducted with these participants excluded. Univariate repeated
measures ANOVA was used to determine group differences across Visit 1
and Visit 2 on the Stroop test, PAL, IED, and SWM, HADS-anxiety
(HADS-A), HADS-depression (HADS-D), PHQ-9 and PSQI scores, and
for plasma cytokines, tryptophan, kynurenine, the kynurenine:-
tryptophan (Kyn:Trp) ratio and CAR, followed by inspection of post-hoc
Tukey Honestly Significant Difference (HSD) tests where significant main
group effects were found. Where Mauchly’s test of sphericity was sig-
nificant, the Greenhouse-Geisser or Huynh-Feldt correction was applied.
Where significant main effects of visit or group by visit interactions were
found, planned comparisons of group differences at each visit individu-
ally were investigated using one-way ANOVA followed by inspection of
post-hoc Tukey HSD tests as appropriate. To determine within group
changes on each measure where main effects of visit, or visit by group
interactions were found, paired samples t-tests with a Bonferroni
correction were carried out within each group. To determine relation-
ships between cognitive performance and biochemical and questionnaire
and clinical measures across visits within CD patients, a composite value
was calculated (mean of Visit 1 and 2) for the Stroop effect, PAL total
Table 2
Summary and group comparisons of mean anxiety, depression, sleep disturbance
and disease activity scores at visit 1 & visit 2.
Healthy
Controls (n ¼
30)
CD (n ¼ 15) UC (n ¼ 7) p-
value
Visit
1
Visit
2
Visit
1
Visit
2
Visit
1
Visit
2
G. Clarke et al. Brain, Behavior, & Immunity - Health 5 (2020) 100093errors, IL-6, IL-8, TNF-α, tryptophan, kynurenine, the Kyn:Trp ratio, the
CAR, HADS-A, HADS-D, PHQ-9, PSQI, and the HBI. Spearman’s rho was
then examined to identify significant relationships between composite
cognitive performance, biochemical and clinical measures.
Non-transformed data are presented as mean  standard error of the
mean (SEM). Effect sizes are reported as partial Eta squared (ηp2). All
statistical procedures were carried out using IBM SPSS Statistics 20.0 for
Windows software package.
3. Results
3.1. Sample characteristics
Group characteristics for healthy control participants, patients with
CD and UC are presented in Table 1 and Table 2. Patients with IBD were
using the following medications at Visit 1; 6-MP (CD n ¼ 7; UC n ¼ 2),
mesalamine (CD n ¼ 3; UC n ¼ 5), adalimumab (CD n ¼ 4), mesalazine
(CD n¼ 2; UC n¼ 1), azathioprine (CD n¼ 2; UC n¼ 1), budesonide (CD
n ¼ 2), and sulfasalazine (CD n ¼ 1). Only one change in medication was
recorded at visit 2 (budesonide: CD n ¼ 1).
3.2. Cognitive performance
3.2.1. Attentional performance (Stroop test) is impaired in Crohn’s disease
Across visits 1 and 2,there was an overall main effect of group (F(2,
49) ¼ 3.824; P ¼ 0.029, ηp2 ¼ 0.135) with patients with CD exhibiting
impaired attentional performance when compared to healthy controls (P
¼ 0.022). Attentional performance in patients with CD was most
impaired at visit 2, when compared to healthy control participants (P ¼
0.002, see Fig. 1a), Healthy control participants exhibited a significant
learning effect in performance between visit 1 and 2 (P ¼ 0.006),
whereas patients with CD (P ¼ 0.66) or UC (P ¼ 0.327), did not.
3.2.2. Visuospatial episodic memory (Paired Associate Learning; PAL) is
impaired in patients with Crohn’s disease and ulcerative colitis
Across visits 1 and 2, there was an overall main effect of group on the
total number of errors on the PAL test (F (2, 49)¼ 5.828; P¼ 0.005, ηp2 ¼
0.192) with patients with CD exhibiting significantly impaired perfor-
mance the PAL when compared with healthy controls (P¼ 0.013) but not
when compared to patients with UC (P ¼ 0.984). A greater number of
errors made on the PAL test by patients with UC approached significance
when compared to healthy controls (P ¼ 0.051). Further analysis
revealed that visuospatial memory performance was most impaired at
visit 2 in both patients with CD (P ¼ 0.008) and patients with UC (P ¼
0.019; see Fig. 1b).
3.2.3. Executive function (intra/extra dimensional shift; IED) is not different
between patients and healthy controls
No significant group differences were identified across visit 1 and 2Table 1
Comparison of group demographics at Visit 1.
Baseline Demographics Healthy
Controls (n ¼
30)
CD (n ¼
15)
UC (n ¼ 7) P-
value
Age 28.23  1.71 31.93 
2.05
35  4.22 .16
Gender: Male (%)
Female (%)
10 (33.3%)
20 (66.7%)
11
(73.3%)
4 (26.7%)
2 (28.6%)
5 (71.4%)
.026*
BMI 23.27  .71 25.47 
.76
23.93 
1.23
.15
WAIS-R Full Scale IQ
(NART conversion)
109.19  1.19 103.16 
2.92
103.11 
5.16
.069
CD, Crohn’s disease; UC, ulcerative colitis; BMI, body mass index; WAIS-R,
Wechsler Adult Intelligence Scale-Revised; NART, National Adult Reading
Test;. Data are mean  S.E.M.
4on executive function (all P > 0.05; see Table 3).
3.2.4. Spatial Working Memory (SWM) is not different between patients and
healthy controls
No significant group differences were identified across Visit 1 and 2
on working memory performance (all P > 0.05; see Table 3).
3.3. The cortisol awakening response (CAR) is blunted at visit 1 and 2 in
patients with Crohn’s disease
Across visit 1 and 2 there was a significant main effect of group (F (2,
45) ¼ 7.267; P ¼ 0.002, ηp2 ¼ 0.244) in which the cortisol awakening
response was significantly blunted in patients with CD when compared to
healthy control participants (P ¼ 0.001) but not when compared to pa-
tients with UC (P ¼ 0.426; see Fig. 2).
3.4. Plasma cytokine levels
3.4.1. IL-6 is elevated at visit 1 and 2 in patients with Crohn’s disease
Across Visit 1 and 2 there a significant main effect of group for plasma
levels of IL-6 (F (2, 49) ¼ 9.453; P < 0.001, ηp2 ¼ 0.278), with higher
levels of IL-6 in patients with CD when compared to healthy controls (P
< 0.001) but not patients with UC (P ¼ 0.081; see Table 4).
3.4.2. IL-8 levels are lower in patients with ulcerative colitis at visit 2
Plasma levels of IL-8 at visit 2 were significantly lower in patients
with UC when compared with patients with CD (P ¼ 0.002) and healthy
control participants (P ¼ 0.014, see Table 4).
3.4.3. TNF-α levels are lower in patients with ulcerative colitis at visit 1 and
2
Analysis of levels of TNF-α across visit 1 and 2 showed a significant
main effect of group (F (2, 49) ¼ 19.995; P < 0.001, ηp2 ¼ 0.449), with
patients with UC having significantly lower levels of TNF-α when
compared to both patients with CD (P < 0.001) and healthy control
participants (P < 0.001; see Table 4).HADS-A 3.6 
.53
3.7 
.72
5.6 
.86
5 
.85
6.86

1.94
5.33

1.45
0.185
HADS-D 1.43
 .32
1.15
 .36
3.2 
.99
2.46
 .86
3.57

1.44
3.5 
1.12
0.029
PHQ-9 1.37
 .39
1.26
 .45
3.33

1.14
2.92

1.07
2.28
 .92
2.83

1.19
HBI Total
Score
(Remission
< 5)
– – 1.57

0.35
2.12

0.51
– – .216#
SCCAI
(Remission
 3)
– – – – 1.43

0.37
2.33

0.33
.058#
HADS-A/D, Hospital Anxiety and Depression Scale- Anxiety/Depression; PHQ-9,
Patient Health Questionnaire; PSQI, Pittsburgh Sleep Quality Index; HBI, Harvey
Bradshaw Index; SCCAI, Short Clinical Colitis Activity Index.Data are mean 
S.E.M.
Fig. 1. Group comparison of a) selective attention and response inhibition on the Stroop test at Visit 1 and Visit 2; b) Visuospatial memory performance on the Paired
Associates Learning (PAL) test at Visit 1 and Visit 2 (**P < 0.01; *P < 0.05). CD, Crohn’s disease; UC, ulcerative colitis. Data are presented as mean  SEM.
Table 3
Mean test scores and group comparisons of performance on the IED and SWM tests at Visit 1 and Visit 2.
Cognitive Test Control CD UC P- value
Baseline 6 Months Baseline 6 Months Baseline 6 Months
IED Total Errors (Adjusted) 22.77  6.19 18.02  3 16.47  3.59 17.56  2.91 31.86  8.26 17.56  2.91 0.086
SWM Total errors 14.27  2.77 15.54  2.41 18.93  5.21 17.65  4.82 16.71  5 14.17  4.48 0.896
IED, Intra-extra dimensional set shift; SWM, Spatial Working Memory; CD, Crohn’s disease; UC, ulcerative colitis. (P-value ¼ ANOVA from repeated measures analysis). Data are
mean  S.E.M.
Fig. 2. Group comparisons of the cortisol awakening response determined using
an area under the curve with respect to ground (AUCg) calculation on all three
measurement time points (upon wakening, 1 h after wakening and 3 h after
wakening) at Visit 1 and 2 (**P < 0.01, *P < 0.05). CD, Crohn’s disease; UC,
ulcerative colitis. Data are presented as mean  SEM.
Table 4
Mean levels and group comparisons of plasma proinflammatory cytokines at Visit 1 a
Proinflammatory Cytokine Control CD
Visit 1 Visit 2 Visit 1
IL-6 (pg/ml) 0.87  0.09 1.32  0.26 2.14  0.41Ϯ
IL-8 (pg/ml) 4.49  0.32 7.81  0.64 6.55  0.83
TNF-α (pg/ml) 4.52  0.24 5.13  0.2 5.52  0.56
IL, interleukin; CD, Crohn’s disease; UC, ulcerative colitis. p-value represents group
control Visit 1; ¥p < 0.001 vs control Visit 2; #p < 0.001 vs CD Visit 2; $p < 0.001 v
Table 5
Mean levels and group comparisons of plasma tryptophan, kynurenine and kynureni
Control CD
Visit 1 Visit 2 Visit 1
Tryptophan 11923  426.35 12122.91  442.79 11002.09  588.32
Kynurenine 522.41  23.90 527.67  23.98 553.35  43.03
Kyn:Trp ratio 0.04  0.0 0.04  0.0 0.05  0.0
CD, Crohn’s disease; UC, ulcerative colitis. p-value represents main group effect from r
2; ¥p < 0.05 vs control Visit 1; #p < 0.001 vs control Visit 2. Data are mean  S.E.M
G. Clarke et al. Brain, Behavior, & Immunity - Health 5 (2020) 100093
53.5. Plasma tryptophan, kynurenine & Kyn:Trp ratio
3.5.1. Tryptophan levels are not different between patients and healthy
controls
Plasma tryptophan levels did not significantly differ between groups
at visit 1 or 2 (all P > 0.05; Table 5).
3.5.2. Kynurenine levels are significantly elevated in patients with Crohn’s
disease at visit 2
A main effect of group for plasma kynurenine levels was evident at
visit 2 (see Table 5) with patients with CD having significantly elevated
levels when compared to healthy control participants (P¼ 0.039) but not
compared to patients with UC (P ¼ 0.286).
3.5.3. Kynurenine: tryptophan (Kyn:Trp) ratio is significantly elevated in
patients with ulcerative colitis at visit 1 and patients with Crohn’s disease at
visit 2
Analysis of the plasma Kyn:Trp ratio across visit 1 and 2 showed a
significant main effect of group (see Table 5), with patients with CDnd Visit 2.
UC p- value
Visit 2 Visit 1 Visit 2
4.06  0.91¥ 2.77  1.75 4.05  3.27 <0.001***
14.08  5.08 11.32  6.08 4.99  2.05# 0.068
6.95  0.77 3.64  0.83$ 1.91  0.64¥# 0.001**
effect from repeated measures ANOVA; **p < 0.01; ***p < 0.001. Ϯp<0.001 vs
s CD Visit 1. Data are mean  S.E.M.
ne:tryptophan ratio at Visit 1 and Visit 2.
UC P-value
Visit 2 Visit 1 Visit 2
12563.59  1003.27Ϯ 11452.74  1226.7 9984.83  828.9 0.413
645.16  44.36 642.2  68.22 542.16  58.9 0.177
0.06  0.01 # 0.06  0.00 ¥ 0.05  0.1 0.023*
epeated measures ANOVA across Visit 1 and 2; *p< 0.05. Ϯp<0.05 vs control Visit
.
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participants (P¼ 0.03), but not when compared with patients with UC (P
¼ 0.997).Table 6
Summary of correlations between averaged Visit 1 and 2 values for selective
attention and response inhibition (Stroop Interference Effect), visuospatial
memory performance (PAL Total Errors), physiological markers, anxiety,
depression and disease activity.
Crohn’s Disease (CD) Group
Stroop Interference Effect (Mean
of visit 1 & 2)
PAL Total Errors (Mean of
visit 1 & 2)
Measure (Mean of visit 1 & 2)
IL-6 -.186 -.032
IL-8 -.207 -.043
TNF-a .368 .154
L-Tryptophan -.304 -.086
L-Kynurenine -.075 -.243
Kyn:Trp Ratio -.107 -.171
CAR (AUCg) .358 .154
HADS-A
(Anxiety)
-.022 .038
HADS-D
(Depression)
.132 .221
PHQ-9
(Depression)
-.126 .005
Disease Activity
(HBI)
-.011 .051
Disease Duration .215 -.022
WAIS IQ -.082 -.490
PAL, Paired Associate Learning; IL, interlukin; TNF-a, tumor necrosis factor-
alpha; Trp:Kyn; kynurenine:tryptophan ratio; HADS-A/D, Hospital Anxiety and
Depression Scale- Anxiety/Depression; HBI, Harvey Bradshaw Index; WAIS-R,
Wechsler Adult Intelligence Scale-Revised.3.6. Correlational analysis
Correlational analysis revealed no significant relationships between
attentional (Stroop Test) or visuospatial memory performance (PAL total
errors), and biochemical measures, self-report psychological or clinical
measures (see Table 6).
4. Discussion
Our primary aim was to prospectively assess cognitive performance in
patients with IBD in clinical remission in comparison to healthy control
participants, with a focus on elaborating on previous findings indicating
a selective attention and response inhibition deficit in these patients with
CD (Kennedy et al., 2014). To our knowledge, this is the first study to
prospectively assess cognitive performance in CD patients and to
examine the role of a range of biomarkers that may impact on cognition.
In agreement with previous findings (Kennedy et al., 2014), we found
that when patients with CD were prospectively followed over a 6 month
period, they displayed a persistent deficit in attentional performance.
Interestingly, patients with UC did not display a similar deficit. In addi-
tion to impaired attentional performance, patients with CD exhibited
significantly impaired visuospatial memory performance across visits.
Reports of cognitive impairment in IBD have been inconsistent
(Berrill et al., 2013; Dancey et al., 2009). A number of reasons may be
proposed to explain these disparate findings including differing levels of
disease activity and medication use in patients, sample characteristics
and approach to subject matching (e.g. by age, IQ or years of education),
or, indeed, differences in the psychometric properties of the cognitive
assessments which were employed. However, a recent structural mag-
netic resonance imaging study reported that patients with CD in clinical
remission have reduced grey matter volume in regions of the dorsolateral
prefrontal cortex and anterior midcingulate cortex (aMCC (Agostini
et al., 2013). Functional alterations in the ACC and the right inferior
frontal gyrus have also been reported (Petruo et al., 2017) in addition to
alterations in brain white matter microstructural properties (Hou et al.,
2020). Regions of the anterior cingulate cortex (e.g. aMCC, posterior
MCC) are heavily involved in attentional decision-making tasks such as
the Stroop (Bush, 2009; Enriquez-Geppert et al., 2013). As such, our
findings compliment these neuroimaging findings and raise the possi-
bility that the structural brain changes which are apparent in patients
with CD in clinical remission are associated with functional impairments
in ACC-mediated cognitive performance.
Interestingly, attention and memory impairments have also been re-
ported in pediatric patients with IBD (Piasecki et al., 2017). However,
additional studies in which both structural neuroimaging and cognitive
testing are performed in the same cohort of patients are needed to verify
this hypothesis. These observations also need to be integrated with the
recent reports of impaired neurocognitive and psychomotor function
across areas of convergent thinking, perceptive abilities and sophisti-
cated operative thinking (Tadin Hadjina et al., 2019) as well as cognitive
inflexibility (Petruo et al., 2017). Emotional processing biases have also
been reported to contribute to co-morbid depression among people with
IBD (Wilkinson et al., 2019) while anxiety symptoms were associated
with slower processing speed, lower verbal learning, and lower working
memory performance (Whitehouse et al., 2019).
Despite not finding any relationships between the biomarkers
measured and cognitive performance in patients with CD, there is sub-
stantial evidence that elevated proinflammatory cytokines (Dantzer,
2009; Quan and Banks, 2007), circulating cortisol (Kennedy et al.) and
kynurenine metabolism (Kennedy et al., 2015; Stone and Darlington,62013) can modulate CNS function and cognitive performance. As such,
we cannot rule out this reflects the difficulty in using correlational
techniques to identify complex non-linear neurobiological relationships.
Conversely, it may reflect a need to measure relationships between these
biochemical parameters and cognition over much longer periods and at
multiple time-points to identify meaningful covariations.
Future studies that are designed to elucidate the impact of disease
activity on cognitive performance are needed. We did not find any re-
lationships between cognitive performance and disease activity. How-
ever, we did not measure additional GI symptoms such as pain or
bloating which may well impinge on cognitive performance. Therefore,
future studies employing a well validated and temporally specific GI
symptom assessment in relation to cognitive performance in IBD are
needed. In addition, our groups differed with respect to gender, and
although the effect of gender on cognitive performance tends to be small
and inconsistent (Weiss et al., 2003), it will be important for future in-
vestigations to examine the role that gender plays in mediating the
impact of pathogenic processes impacting on cognitive performance in
IBD. Moreover, such studies should aim to delineate the role of key
factors such as menstruation status and age in impaired cognitive per-
formance in IBD.
In conclusion, patients with CD in clinical remission, followed pro-
spectively, exhibit a consistent impairment in attentional performance
and visuospatial memory on the PAL test. Accumulating evidence sup-
ports the view that patients with IBD should be monitored for psycho-
logical well-being (Gracie et al., 2018). Moreover, evidence for the
efficacy of antidepressants is now emerging in IBD (Mikocka-Walus et al.,
2020). Our findings, taken with previous reports, extend the psycho-
logical component of CD to the cognitive domain and indicate that
altered attention may be related to neurobiological changes in the
function of ACC brain regions. This has significant clinical implications
by raising the issue of how this deficit impacts on the functional capacity
of patients, their experience of illness and their quality of life. Thus,
future interventional studies should aim to identify which therapeutic
strategies alleviate not only the inflammatory GI symptoms, but also
co-morbid cognitive impairment in CD.
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